What to do after stopping GLP-1 treatment starts with a plan for what comes next. In a new Cleveland Clinic study, people who stopped without another obesity medicine or surgery remained about 4% below their original weight. The averages were larger with continued medication, a switch, or surgery. These findings describe groups; they don't choose a treatment for you.

GLP-1 medicines act on a gut-hormone signal involved in appetite and blood sugar. The study covered semaglutide, the medicine in Ozempic and Wegovy, and tirzepatide, the medicine in Mounjaro and Zepbound.

What to do after stopping GLP-1: the new findings

As of November 19, 2026, the day this article was written, a study published November 14 in eClinicalMedicine compares five treatment paths. Hamlet Gasoyan and colleagues examined records from 20,486 Cleveland Clinic patients in Ohio and Florida.

Patients had used either medicine for at least three months, according to the hospital's November 14 release. The paper used records spanning 2021–2025.

This was a target trial emulation: researchers used health records to imitate a trial they could not run. Patients weren't assigned treatments by chance. Statistical adjustments accounted for recorded differences, but cannot remove every difference between groups.

Treatment path Estimated average weight loss at two years
Stopped without another obesity medicine or surgery 4.0%
Switched to another obesity medicine 8.2%
Continued the original semaglutide or tirzepatide 10.9%
Switched between semaglutide and tirzepatide 16.0%
Had bariatric surgery, meaning weight-loss surgery 28.2%

These are the paper's per-protocol estimates, which estimate outcomes if patients stayed with each treatment path. Weight change runs from the first medication fill to two years after entry into the comparison. The percentages include weight lost before a switch or stop.

What the 4% result means after stopping

The stopping group finished lighter than at the original start of treatment, on average. That does not mean people lost another 4% after their last dose. It also doesn't mean they kept 4% of the pounds previously lost. The denominator is their original body weight.

Stopping was defined in the paper as a medication supply gap longer than 90 days. This isn't a study of one late dose.

For the practical changes after treatment ends, the guides to stopping semaglutide and stopping tirzepatide explain the separate evidence. A group average cannot predict one person's appetite or weight over the next few months.

Switching direction matters

People who began on semaglutide and switched to tirzepatide had greater average weight loss than those who stayed on semaglutide.

For people who began on tirzepatide, the direction was different. Staying on tirzepatide was associated with more weight loss than switching to semaglutide. The pooled 16% figure therefore isn't evidence that changing medicines in either direction is better than staying put.

The guide to switching from semaglutide to tirzepatide covers the prescription questions. This records study cannot supply a dose conversion, a starting dose, or a date for the first dose of a different medicine. The prescriber sets those details.

Another medication was also a separate path in the study. Its average combines several drugs, so the result cannot be assigned to every medicine in that group.

What the comparison cannot decide

The largest weight-loss average does not establish the best treatment for a particular person. Patients and clinicians chose different paths; who reaches surgery is not random. Health history, access and treatment preferences can differ in ways records don't fully capture.

All records came from one health system. Adjusting for measured differences makes the comparison more useful, but does not turn it into a randomized trial.

The hospital's release uses “best” in its headline. The study cannot establish a universal winner. A separate Cleveland Clinic surgery study examined surgery after medication intolerance or limited weight loss. That is a different question from comparing these five paths.

The paper wasn't limited to weight. It also measured longer-term blood sugar in people with diabetes, a condition with high blood sugar. Blood pressure was tracked in people with high blood pressure. The authors note that the study did not compare side effects across the five paths. Neither a scale reading nor those measurements settles the full balance of side effects, costs and treatment burden.

Averages also don't explain why an individual stopped. That reason belongs at the center of the next prescribing conversation.

How this fits with withdrawal trials

Earlier trials asked a narrower question: what happens when people already taking a medicine are switched by chance to placebo, a look-alike treatment without active medicine?

STEP 4, published in JAMA in 2021, found average regain after that switch. Its study guide explains who reached the comparison. The SURMOUNT-4 guide covers the corresponding tirzepatide trial.

Those planned withdrawals differ from everyday decisions to switch medicines or have surgery. The new study adds information about those choices; it doesn't erase the earlier evidence.

What the findings mean for a prescription

A prescribing discussion starts with the reason for a change, the medicine and dose history, symptoms, other health conditions, and treatment goals. The study of heart risk after stopping covers a separate outcome; weight alone cannot answer that question.

Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, prepared for an individual prescription. It is different from an FDA-approved product: the formulation offered here is not FDA-approved. These study averages do not establish the outcomes of that specific preparation.

As of November 19, 2026, the day this article was written, FDA's compounding explanation, marked current September 16, 2025, says it does not verify compounded drugs' safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

What to watch next

Stronger comparisons would track why people stop, their side effects and access barriers, and outcomes across different health systems. Longer follow-up would help show how the paths hold up over time.

This study is a reason to discuss a continuing care plan with the prescriber, not to stop or switch medication independently. It does not override urgent safety instructions for symptoms. At Promise, a licensed provider reviews every request, and not everyone qualifies.